Onasemnogen abeparvovek (Slovenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Onasemnogen abeparvovek" in Slovenian language version.

refsWebsite

Global rank Slovenian rank

447^th place

409^th place

68^th place

28^th place

low place

9,812^th place

399^th place

169^th place

4^th place

8^th place

low place

low place

1theguardian.com

12^th place

44^th place

5^th place

10^th place

49^th place

97^th place

drugs.com

Use During Pregnancy and Breastfeeding

europa.eu

ema.europa.eu

https://www.ema.europa.eu/en/documents/product-information/zolgensma-epar-product-information_sl.pdf Povzetek glavnih značilnosti zdravila Zolgensma, vpogled: 14. 9. 2020.
https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma, vpogled: 14. 9. 2020.

fda.gov

»FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality«. U.S. Food and Drug Administration (FDA). 24. maj 2019. Pridobljeno 18. novembra 2019.
»Zolgensma«. FDA. 6. avgust 2019. Pridobljeno 1. novembra 2019.
»FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality«. FDA. 11. september 2019. Pridobljeno 18. novembra 2019.

nih.gov

dailymed.nlm.nih.gov

»Zolgensma- onasemnogene abeparvovec-xioi kit full prescribing information«. DailyMed. 24. maj 2019. Pridobljeno 18. novembra 2019.

novartis.com

»Novartis successfully completes acquisition of AveXis, Inc« (tiskovna objava). Novartis. Pridobljeno 6. oktobra 2018.
»Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1«. Novartis. Pridobljeno 4. decembra 2018.

reuters.com

Miller, John (30. oktober 2019). »Novartis' Zolgensma study halted by FDA amid safety questions«. Reuters. Pridobljeno 30. oktobra 2019.

sma-europe.eu

»AveXis receives FDA approval for Zolgensma, the first gene therapy for paediatric patients with SMA«. SMA Europe. 25. maj 2015. Pridobljeno 25. maja 2019. This treatment was pioneered by Dr Martine Barkats, from the Institut de Myologie in France.

theguardian.com

»$2.1m Novartis gene therapy to become world's most expensive drug«. The Guardian. London. Reuters. 25. maj 2019. ISSN 0261-3077. Pridobljeno 25. maja 2019.

worldcat.org

»$2.1m Novartis gene therapy to become world's most expensive drug«. The Guardian. London. Reuters. 25. maj 2019. ISSN 0261-3077. Pridobljeno 25. maja 2019.